Share this NATF page   

The DAWN Trial

At the 3rd annual European Stroke Organization Conference the results of the DAWN Trial were presented. The results suggest that an endovascular thromboectomy can reduce a stroke patient’s risk of becoming disabled up to 24 hours after the stroke. Previous clinical data had only proven the benefit of this procedure in patients within six hours after their stroke.

The DAWN Trial was an international, multi-center, blinded endpoint assessment, randomized study. It compared mechanical thrombectomy using the Trevo Retriever combined with medical therapy and medical therapy alone. Patients involved in the trial had experienced an acute ischemic stroke 6 to 24 hours before and had failed IV t-PA therapy or were contraindicated for IV t-PA administration.


Here is a closer look at the Trevo Retriever

The results from this trial have the potential to change how stroke patients are treated and what type of life they lead after their stroke. Stroke can lead to major disabilities including physical weakness, vision impairment, trouble speaking, mental impairment, memory loss, and more

“Treating acute stroke patients with large vessel occlusion who present later than six hours from last seen well has the potential to help thousands of stroke patients around the world,” said co-principal investigator Tudor Jovin, MD, from the University of Pittsburgh Medical Center, in a press release from Stryker. “These patients, many of whom present to the hospital outside of the six hour time window could have a better chance for an independent life with improved clinical outcomes.”

"Our results show that for every 100 patients treated with endovascular therapy, 49 will have a less disabled outcome as a result of treatment, including 36 who will be functionally independent," Dr. Jovin said in an article by Medscape Medical News. "These results greatly expand the population of patients who can benefit from mechanical thrombectomy for stroke, to significantly reduce functional impairment in the mostly severely affected patients," he added. 

"Time is still obviously very important and the earlier the treatment is given the better the results, but we have shown in this trial that it shouldn't be the only factor that determines whether we consider endovascular therapy," he continued.

To learn more about this study, visit the trial page here.

Time is of the essence when it comes to stroke. Know the signs and symptoms to ensure you and your loved ones receive treatment as quickly as possible.

 

About NATF

Patients

Professionals

Events


Membership

Giving to NATF

North American Thrombosis Forum
368 Boylston Street
Brookline, MA 02445

617 - 730 - 4120


NATF is a 501(c) nonprofit

Contact Us

© 2012 North American Thrombosis Forum


Web Development by MTC